Figure 5.

aNK cells alone and in combination with dinutuximab decrease overall disease burden following primary tumor resection. (A) Images of disease burden prior to treatment and 2 days after the completion of treatment are shown from mice following resection of primary tumors created by CHLA-136-Fluc and CHLA-255-Fluc cells. (B) Bioluminescent imaging was performed weekly and tumor flux (photons/sec) measurements were adjusted to baseline observations. The area under the curve (AUC) was calculated and linear regression was used to assess treatment effects.